- Full Time Employees
- 52
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seoul South Korea
- IPO Date
- May 4, 2023
- Business
- S.Biomedics Co., Ltd. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the research, development, and commercialization of advanced stem cell therapies and regenerative medicine products. Founded in 2005 and headquartered in Seoul, South Korea, the company develops novel therapeutics based on two proprietary biological platforms: Targeted Embryonic Stem Cell Differentiation (TED) technology, which standardizes the high-purity differentiation of pluripotent stem cells into specific neural cell types; and Functionally Enhanced Cell Spheroid (FECS) technology, a three-dimensional cell spheroid culture method engineered to enhance cell viability, paracrine secretion, and tissue engraftment. S.Biomedics operates across the biotechnology, regenerative medicine, and medical aesthetics sectors, targeting intractable neurological, vascular, and degenerative conditions for healthcare institutions and aesthetic clinics in South Korea and global markets. The company's core product and development portfolio comprises clinical-stage cell therapy pipeline programs, including TED-A9, a human embryonic stem cell-derived dopaminergic neural precursor cell therapy for the treatment of Parkinson's disease; TED-N, a stem cell-derived neural progenitor cell therapy for subacute spinal cord injury; FECS-Ad, an adipose-derived stem cell spheroid therapy for critical limb ischemia; and FECS-DF, a dermal fibroblast spheroid treatment for deep tissue regeneration and wrinkle correction; early-stage research programs, including TED-R for macular degeneration, CF-TED-N for ischemic stroke, and CF-FECS-DF for intractable wound healing; and aesthetic medical products and cosmeceuticals commercialized through its subsidiary, S.THEPHARM Co., Ltd., consisting of the QTFill line of cross-linked hyaluronic acid dermal fillers; QTL and QTL 365 polydioxanone lifting threads; and QTCell and QTOn cell culture-derived anti-aging topical solutions. In recent developments, S.Biomedics completed its initial public offering on the KOSDAQ market of the Korea Exchange under the ticker symbol 304360. The company established a strategic development and manufacturing partnership with Catalent, Inc. to support global supply and regulatory compliance for its lead asset. In clinical advancements, S.Biomedics announced successful long-term Phase 1/2a clinical trial results for TED-A9, demonstrating favorable safety and significant motor improvement in patients with Parkinson's disease, and initiated regulatory preparations for an Investigational New Drug application with the United States Food and Drug Administration to expand into multi-regional registrational clinical trials. The company has also raised growth capital via convertible bond issuances to fund late-stage clinical programs and expanded out-licensing discussions with global pharmaceutical partners.